$BMY is down after good results.Street doesn’t believe they can replace the Revlimid lost profits starting in 2022. I’m more than willing to be patient, collect the 3.5% dividend and following the strengthening balance sheet. $BMY, Bristol-Myers Squibb Company / H1 notes via user